This page contains exclusive content for the member of the following sections: TTS, CTS
Presenter: Carmen, Fotino, Miami, United States
Authors: R. Damaris Molano1,2,3,4,5, Carmen Fotino1,2,3,4,5, Ann-Christina Brady1,2,3,4,5, Nicola Bocca1,2,3,4,5, Simona Marzorati1,2,3,4,5, Elsie Zahr-Akrawi1,2,3,4,5, Luca Inverardi1,2,3,4,5, Camillo Ricordi1,2,3,4,5, Peter Buchwald1,2,3,4,5, Antonello Pileggi 1,2,3,4,5
R. Damaris Molano1,2,3,4,5, Carmen Fotino1,2,3,4,5, Ann-Christina Brady1,2,3,4,5, Nicola Bocca1,2,3,4,5, Simona Marzorati1,2,3,4,5, Elsie Zahr-Akrawi1,2,3,4,5, Luca Inverardi1,2,3,4,5, Camillo Ricordi1,2,3,4,5, Peter Buchwald1,2,3,4,5, Antonello Pileggi 1,2,3,4,5
1Diabetes Research Institute, University of Miami, Miami, FL, United States; 2Medicine, University of Miami Miller School of Medicine, Miami, FL, United States; 3Microbiology & Immunology, University of Miami Miller School of Medicine, Miami, FL, United States; 4Surgery, Microbiology and Immunology, Biomedical Engineering, University of Miami, Miami, FL USA, FL, United States; 5Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL, United States
Replacement of beta-cell function via intrahepatic islet transplantation restores metabolic control in patients with type 1 diabetes. The need for systemic immunosuppression and its associated untoward side effects currently limit the indication of islet transplantation to the most severe cases of instable diabetes. Tissue engineering is opening new opportunities for the development of more efficient biological treatments for diabetes. We have previously reported that transplantation of syngeneic islets corrects diabetes into prevascularized, subcutaneous biohybrid devices (BHD). To overcome the need for chronic systemic immunosuppression, we sought to evaluate the effects of localized immuno-suppression (LIS) on allogeneic islet allograft survival into BHD.
By viewing the material on this site you understand and accept that:
The Transplantation Society
International Headquarters
505 Boulevard René-Lévesque Ouest
Suite 1401
Montréal, QC, H2Z 1Y7
Canada